LadRx Corp Files Q3 2024 10-Q

TL;DR

LadRx Corp's Q3 10-Q is in. Check financials.

AI Summary

LadRx Corp filed its 10-Q for the period ending September 30, 2024. The company, formerly known as CYTRX CORP, is in the biological products sector. Its principal executive offices are located in Los Angeles, California.

Why It Matters

This filing provides investors with the latest financial performance and operational updates for LadRx Corp, crucial for understanding the company's current standing and future prospects.

Risk Assessment

Risk Level: low — This is a standard quarterly financial filing with no immediate red flags or significant new information presented.

Key Players & Entities

• LadRx Corp (company) — Filer
• CYTRX CORP (company) — Former company name
• 20240930 (date) — Period of report
• 20241114 (date) — Filing date
• 11726 SAN VICENTE BOULEVARD SUITE 650 LOS ANGELES CA 90049 (address) — Business and mailing address

FAQ

Filing Documents

• form10-q.htm (10-Q) — 594KB
• ex31-1.htm (EX-31.1) — 11KB
• ex31-2.htm (EX-31.2) — 11KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• 0001493152-24-045299.txt ( ) — 3043KB
• ladx-20240930.xsd (EX-101.SCH) — 21KB
• ladx-20240930_cal.xml (EX-101.CAL) — 28KB
• ladx-20240930_def.xml (EX-101.DEF) — 102KB
• ladx-20240930_lab.xml (EX-101.LAB) — 214KB
• ladx-20240930_pre.xml (EX-101.PRE) — 164KB
• form10-q_htm.xml (XML) — 389KB

— FINANCIAL INFORMATION

PART I. — FINANCIAL INFORMATION 4 Item 1. Condensed Financial Statements (unaudited) 4 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 14 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 21 Item 4.

Controls and Procedures

Controls and Procedures 21

— OTHER INFORMATION

PART II. — OTHER INFORMATION 22 Item 1.

Legal Proceedings

Legal Proceedings 22 Item 1A.

Risk Factors

Risk Factors 22 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 22 Item 3. Defaults Upon Senior Securities 22 Item 4. Mine Safety Disclosures 22 Item 5. Other Information 22 Item 6. Exhibits 22

SIGNATURES

SIGNATURES 23 INDEX TO EXHIBITS 24 2 Forward Looking Statements All regarding our business strategy, business plan and research and development activities, our future financial results, and other future events. These statements include forward-looking statements both with respect to us, specifically, and the biotechnology industry, in general. In some cases, forward-looking statements can be identified by the use of terminology such as "may," "will," "expects," "plans," "anticipates," "estimates," "potential" or "could" or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, there can be no assurance that such expectations or any of the forward-looking statements will prove to be correct, and actual results could differ materially from those projected or assumed in the forward-looking statements. All forward-looking statements involve inherent risks and uncertainties, and there are or will be important factors that could cause actual results to differ materially from those indicated in these statements. We believe that these factors include, but are not limited to, the factors discussed in this section and under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Annual Report"), which should be reviewed carefully. If one or more of these or other risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results may vary materially from what we anticipate. Please consider our forward-looking statements in light of those risks as you read this Quarterly Report. We undertake no o

View Full Filing

View this 10-Q filing on SEC EDGAR